|2.77||-0.0400||-1.42%||Vol 62.83K||1Y Perf 133.33%|
|Dec 2nd, 2022 11:24 DELAYED|
|-0.07 -2.48%||- -|
|Target Price||10.00||Analyst Rating||Hold 3.00|
|Potential %||261.01||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||0.78||Earnings Rating||Neutral|
|Market Cap||4.96M||Earnings Date||21st Dec 2022|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||21st Dec 2022|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||5.92M|
|Avg. Monthly Volume||2.31M|
|Avg. Quarterly Volume||783.85K|
OncoSec Medical Incorporated (NASDAQ: ONCS) stock closed at 2.81 per share at the end of the most recent trading day (a -1.06% change compared to the prior day closing price) with a volume of 464.07K shares and market capitalization of 4.96M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 46 people. OncoSec Medical Incorporated CEO is Daniel J. O'Connor.
The one-year performance of OncoSec Medical Incorporated stock is 133.33%, while year-to-date (YTD) performance is 191.79%. ONCS stock has a five-year performance of -86.47%. Its 52-week range is between 2.52 and 34.76, which gives ONCS stock a 52-week price range ratio of 0.78%
OncoSec Medical Incorporated currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.75, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -87.47%, a ROC of -118.43% and a ROE of -154.68%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from OncoSec Medical Incorporated, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. OncoSec Medical Incorporated’s next earnings report date is 21st Dec 2022.
The consensus rating of Wall Street analysts for OncoSec Medical Incorporated is Hold (3), with a target price of $10, which is +261.01% compared to the current price. The earnings rating for OncoSec Medical Incorporated stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
OncoSec Medical Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
OncoSec Medical Incorporated has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.80, ATR14 : 0.78, CCI20 : -20.26, Chaikin Money Flow : 0.00, MACD : 0.54, Money Flow Index : 88.69, ROC : -33.10, RSI : 51.25, STOCH (14,3) : 7.29, STOCH RSI : 0.07, UO : 32.63, Williams %R : -92.71), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of OncoSec Medical Incorporated in the last 12-months were:
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.